Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease*S⃞

  title={Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease*S⃞},
  author={Qiaojun Fang and AndrewD . Strand and Wendy Law and V{\'i}tor Marcel Faça and Matthew P. Fitzgibbon and Nathalie Hamel and Benoit Houle and Xin Liu and Damon H. May and Gereon Poschmann and Line Roy and Kai St{\"u}hler and Wantao Ying and Jiyang Zhang and Zhaobin Zheng and John J. M. Bergeron and Samir M. Hanash and Fuchu He and Blair R. Leavitt and Helmut E. Meyer and Xiaohong Qian and Martin McIntosh},
  journal={Molecular \& Cellular Proteomics : MCP},
  pages={451 - 466}
We integrated five sets of proteomics data profiling the constituents of cerebrospinal fluid (CSF) derived from Huntington disease (HD)-affected and -unaffected individuals with genomics data profiling various human and mouse tissues, including the human HD brain. Based on an integrated analysis, we found that brain-specific proteins are 1.8 times more likely to be observed in CSF than in plasma, that brain-specific proteins tend to decrease in HD CSF compared with unaffected CSF, and that 81… 

Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research

The results support the hypothesis that natural variability greatly impacts cerebrospinal fluid protein biomarkers and suggest controlling the variability of each protein to distinguish between good and bad biomarker candidates, e.g., by utilizing reference change values in the process of evaluating potential biomarkers in future studies.

Alzheimer disease pathology and the cerebrospinal fluid proteome

Cerebrospinal fluid proteomes are measured to explore their association with well-established markers of core AD pathology and report strong evidence of previously reported CSF proteins and several novelCSF proteins specifically associated with amyloid pathology or neuronal injury and tau hyperphosphorylation.

Cerebrospinal Fluid Biomarkers for Huntington's Disease.

The need for large-scale, standardized CSF collections with detailed phenotypic data to validate and qualify much-needed CSF biomarkers for clinical trial use in HD is reflected.

Decreased Neuro‐Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis

The CSF proteome of patients with a clinically isolated syndrome of demyelination (CIS, a first attack of multiple sclerosis) is compared to the CSF Proteome of control patients to identify differentially abundant proteins.

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease

This study highlights the importance of knowing the carrier and removal status of canine coronavirus, as a source of infection for Huntington's disease, which can be a precursor to disease progression.

Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer’s Disease Patients: A Pilot Study

Based on the CSF EV proteomics, these data indicate that three proteins, HSPA1A, NPEPPS and PTGFRN, may be used to monitor the progression of MCI to AD.

In-depth Exploration of Cerebrospinal Fluid by Combining Peptide Ligand Library Treatment and Label-free Protein Quantification*

The combinatorial peptide ligand library technology (ProteoMiner) is used to reduce the dynamic range of protein concentration in CSF and unmask previously undetected proteins by nano-LC-MS/MS analysis on an LTQ-Orbitrap mass spectrometer, finding that the method is reproducible and applicable for label-free quantification of series of samples processed in parallel.

Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese.

It is concluded that the interaction of Mn and mutant HTT may suppress proteomic phenotypes of YAC128Q mice, which could reveal potential targets in novel treatment strategies for HD.

Analyzing Cerebrospinal Fluid Proteomes to Characterize Central Nervous System Disorders: A Highly Automated Mass Spectrometry-Based Pipeline for Biomarker Discovery.

This chapter describes the whole proteomic workflow to analyze human CSF, and develops a scalable automated proteomic pipeline (ASAP2) for biomarker discovery, compatible with larger clinical research studies in terms of sample size, while still allowing several hundred proteins to be measured in CSF by MS.

Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*

A novel panel of CSF peptides, derived from SPP1, LRP1, CSF1R, EPHA4, and TIMP 1, could be used to assist in clinical diagnosis of PD and has the potential to help monitoring or predicting disease progression.



Brain-derived proteins in the CSF, do they correlate with brain pathology in CJD?

The results indicate that the alteration of levels of brain-derived proteins in the CSF does not only reflect the degree of neuronal damage, but it is also modified by the localization on the brain pathology.

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

This review deals with the recent progress that has been made in identification, quantification and subsequent validation of brain-specific proteins in CSF for the diagnosis of various neurodegenerative disorders.

Influence of Huntington's disease on the human and mouse proteome.

Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach.

An in-depth identification of glycoproteins in human CSF is reported using a complementary proteomic approach which integrated hydrazide chemistry and lectin affinity column for glycoprotein enrichment, followed by multidimensional chromatography separation and tandem mass spectrometric analysis.

A new procedure for detecting brain-specific proteins in cerebrospinal fluid

The reduction of thetransthyretin-isoform in CSF in AD may reflect an absorption of transt Hyretin to the amyloid deposits in the senile plaques.

Regional and cellular gene expression changes in human Huntington's disease brain.

It is concluded that mRNA changes are not attributable to cell loss alone, and data from bona fide HD brains comprise an important reference for hypotheses related to HD and other neurodegenerative diseases.

Alterations in the Mouse and Human Proteome Caused by Huntington’s Disease*

It is demonstrated for the first time at the protein level that α1-antitrypsin and αB-crystalline both decrease in expression over the course of Huntington’s disease, demonstrating that the disease exerts its influence outside the brain of transgenic mice at theprotein level.

A combined dataset of human cerebrospinal fluid proteins identified by multi‐dimensional chromatography and tandem mass spectrometry

This report summarizes the efforts to comprehensively characterize the human CSF proteome to date by utilizing several different separation methodologies and mass spectrometric platforms that greatly enhanced the identification coverage and the depth of protein profiling of CSF to characterize CSFroteome.

The quest for brain disorder biomarkers.

These efforts to identify biomarkers for affective and neurological disorders range from classical proteomics approaches such as two dimensional gel electrophoresis and mass spectrometry to phage display screens with cerebrospinal fluid antibodies.

Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

It is discovered that skeletal muscle is also a target of polyglutamine-related perturbations in gene expression, showing changes in mRNAs that are dysregulated in brain and also muscle-specific m RNAs.